US push, not IP waiver, will raise vaccine supply
The United States said it will now back the initiative to waive IP rights on vaccine-manufacturing capability transfers
You must be signed in to read this analysis
What is this?
This summary is from the Oxford Analytica Daily Brief, which analyses geopolitical, economic, social, business and industrial developments on a global and regional basis, providing clients with timely, authoritative analysis every business day of the year. Find out more about the Oxford Analytica Daily Brief, or request a trial.
This summary refers to the following article(s).